KEI Memo on U.S. Legislation to cap price increases on prescription drugs and to enhance the transparency of R&D costs

On April 30, 2019, KEI issued a memorandum to Congress concerning recent proposed measures to cap drug price increases and to increase the transparency of pharmaceutical research and development costs.  Congress is currently considering several bills that touch on these… Continue Reading

KEI asks NIST to extend comment period on their Special Publication 1234 Draft Green Paper on Return on Public Investment

Today KEI asked the Department of Commerce National Institute of Standards (NIST) to publish a notice in the Federal Register inviting comments on their Special Publication 1234, Draft Green Paper on Return on Public Investment, with an extended deadline. The… Continue Reading

2019: KEI Comments Submitted to USTR Special 301 Review

On Thursday February 7, 2019, KEI submitted comments and intent to testify at the hearing for the 2019 US Trade Representative’s Special 301 review process. This year’s hearing will take place on Wednesday February 27, 2019 at the Office of… Continue Reading

KEI Comments Regarding the NIST Special Publication 1234 Draft Green Paper on Return on Public Investment

KEI filed comments on the NIST Draft Green paper on the return from investment on federally funded R&D (See: https://www.keionline.org/29518). We expect the comment period to be extended, but filed this on January 9, 2018, as an initial submission. KEI-comments-NIST-SP-1234-ROI-9Jan2018… Continue Reading

KEI Intent to Testify and Testimony Summary/Comments on Negotiating Objectives for a U.S.-European Union Trade Agreement (USEUTA)

DATE: December 10, 2018 Intent to Testify and Testimony Summary/Comments on Negotiating Objectives for a U.S.-European Union Trade Agreement (USEUTA) Luis Gil Abinader. Knowledge Ecology International 1621 Connecticut Avenue, Northwest, Suite 500, Washington, DC 20009. Phone number +1.202.332.2670. Federal Register… Continue Reading